
Jonathan A. Ledermann, MD, discusses the rationale for the randomized, double-blind, placebo-controlled, phase III ARIEL3 trial which explored rucaparib as maintenance therapy in women with high-grade, recurrent ovarian cancer who previously received platinum-based chemotherapy.


